Results 191 to 200 of about 29,229,093 (355)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Optimization of Deuteron Irradiation of ¹⁷⁶Yb for Producing ¹⁷⁷Lu of High Specific Activity Exceeding 3000 GBq/mg. [PDF]

Molecules, 2023
Shao L.
europepmc   +1 more source

Activation profile of Mycobacterium tuberculosis-specific CD4+ T cells reflects disease activity, irrespective of HIV status [PDF]

, 2016
Gideon, HP, Goliath, RT, Oni, T, Riou, C, Wilkinson, KA, Wilkinson, RJ   +5 more
core   +1 more source

ChIP-seq accurately predicts tissue-specific activity of enhancers

Nature, 2009
A. Visel, M. Blow, Zirong Li, Tao Zhang, J. Akiyama, Amy Holt, I. Plajzer-Frick, Malak Shoukry, Crystal Wright, Feng Chen, Veena Afzal, B. Ren, E. Rubin, L. Pennacchio   +13 more
semanticscholar   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

A semi-solid in vitro biofilm model for evaluating antimicrobial potency and biofilm-specific activity. [PDF]

Biofilm
Fuglsang-Madsen A, Kvich LA, Henriksen NL, Kristensen R, Henriksen JR, Hansen AE, Bjarnsholt T, Jakobsen TH.   +7 more
europepmc   +1 more source

Site-Specific Activity-Based Protein Profiling Using Phosphonate Handles. [PDF]

Mol Cell Proteomics, 2023
van Bergen W, Hevler JF, Wu W, Baggelaar MP, Heck AJR.   +4 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

RelabotulinumtoxinA, a Ready-to-Use Formulation Neuromodulator Manufactured with PEARL™ Technology to Maintain High Biological and Specific Activity. [PDF]

Toxins (Basel)
Ståhl U, Lekholm E, Hamnevik E, Fredriksson R, Shridharani SM, Taghetchian K, Cohen JL, Nestor MS, Liljegren Sundberg Å.   +8 more
europepmc   +1 more source

Motor cortical influence relies on task-specific activity covariation. [PDF]

Cell Rep, 2022
Warriner CL, Fageiry S, Saxena S, Costa RM, Miri A.   +4 more
europepmc   +1 more source